LOGO@2x.png
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
March 28, 2024 08:00 ET | 4D Molecular Therapeutics, Inc.
Conducted initial pivotal study interactions with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA); Company has clear registration path for 4D-710 for treatment of...
LOGO@2x.png
4DMT to Participate in Upcoming Investor Conferences
March 04, 2024 08:00 ET | 4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full...
LOGO@2x.png
4DMT Reports Full Year 2023 Financial Results and Operational Highlights
February 29, 2024 16:05 ET | 4D Molecular Therapeutics, Inc.
Presented positive interim data from randomized Dose Expansion cohort of the Phase 2 PRISM study evaluating 4D-150 in wet AMD patients with severe disease activity and high treatment burden, enabling...
LOGO@2x.png
4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024
February 12, 2024 08:00 ET | 4D Molecular Therapeutics, Inc.
4D-310 demonstrated clinically meaningful cardiac endpoint improvements through 12-24 months in contractility (echocardiography), peak VO2 (cardiopulmonary exercise testing) and/or cardiac quality of...
LOGO@2x.png
4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
February 06, 2024 23:27 ET | 4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a leading clinical-stage genetic medicines company focused on unlocking the full potential of...
LOGO@2x.png
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
February 05, 2024 16:05 ET | 4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a leading clinical-stage genetic medicines company focused on unlocking the full potential of...
LOGO@2x.png
4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD
February 03, 2024 17:00 ET | 4D Molecular Therapeutics, Inc.
51 wet AMD patients with severe disease activity (mean of 442 µm central subfield thickness & presence of retinal fluid) and high treatment burden (mean of 10 anti-VEGF injections in preceding 12...
LOGO@2x.png
4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden
January 29, 2024 08:00 ET | 4D Molecular Therapeutics, Inc.
Initial interim landmark data analysis (N=50 at 24 Weeks) will be presented by Arshad M. Khanani, M.D., M.A., FASRS, Principal Investigator of the PRISM clinical trial at Angiogenesis, Exudation, and...
LOGO@2x.png
4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease
January 23, 2024 08:00 ET | 4D Molecular Therapeutics, Inc.
4D-710 has demonstrated promising, reproducible, CFTR expression significantly above normal levels for seven patients across Cohorts 1 & 2 (1E15-2E15 vg) and durable improvement or stabilization...
LOGO@2x.png
4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates
January 04, 2024 08:00 ET | 4D Molecular Therapeutics, Inc.
Poised for multiple meaningful catalysts in 2024 driven by strong clinical progress across large market programs in wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and...